0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, End User, Mode of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, End User, Mode of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, End User, Mode of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532841
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Heart Failure Therapeutics Market grew from USD 26.16 billion in 2024 to USD 29.10 billion in 2025. It is expected to continue growing at a CAGR of 10.71%, reaching USD 48.18 billion by 2030.

Unveiling the Heart Failure Therapeutics Arena with Strategic Perspectives

Heart failure remains a critical challenge within global healthcare systems, affecting millions of lives and driving substantial clinical and economic burdens. Recent advancements in pharmacology, diagnostics, and patient management protocols have reshaped therapeutic pathways, yet gaps persist in translating innovation into improved outcomes for diverse patient populations. The convergence of demographic shifts, evolving regulatory landscapes, and heightened emphasis on value-based care calls for a nuanced understanding of market dynamics and emergent trends.

This executive summary distills the most salient findings from a comprehensive examination of the heart failure therapeutics sector. From transformative scientific breakthroughs to shifting reimbursement models, our analysis illuminates the factors reshaping treatments and access. Whether you are a pharmaceutical executive charting your next development cycle or an investor evaluating strategic opportunities, this overview will equip you with the critical intelligence required to navigate complexity and drive growth.

Transformative Shifts Redefining Heart Failure Treatment Pathways

In recent years, heart failure treatment has undergone a profound metamorphosis, propelled by breakthroughs in drug classes and digital health integration. Traditional reliance on ACE inhibitors and beta blockers has given way to novel modalities, including sodium-glucose cotransporter 2 inhibitors, which offer dual benefits in glycemic control and cardioprotection. At the same time, precision medicine approaches have gained traction, enabling stratified therapies tailored to genetic and biomarker profiles.

Regulatory agencies have responded to these scientific advances by streamlining accelerated approval pathways, thereby expediting access to first-in-class and best-in-class assets. Concurrently, patient engagement models have shifted from episodic care toward continuous remote monitoring, supported by telehealth platforms and wearable sensors. This real-time data feedback loop fosters proactive intervention, reducing hospital readmissions and enhancing quality of life. Together, these paradigm shifts underscore a transformative era in which collaboration among stakeholders-pharma, payers, providers, and patients-reshapes the heart failure landscape.

Assessing the Impact of U.S. Tariffs on Therapeutic Accessibility

The introduction of new tariff measures in 2025 by the United States presents a complex matrix of challenges and opportunities for heart failure therapeutics. Higher duties on imported active pharmaceutical ingredients have the potential to inflate production costs for drug manufacturers, prompting firms to reevaluate supply chain strategies and sourcing priorities. In response, some companies are accelerating plans to onshore manufacturing capabilities or diversify ingredient suppliers across alternative geographies.

These cost pressures may also cascade to downstream stakeholders, influencing pricing negotiations with payers and reimbursement authorities. While some firms might absorb a share of the added expense to preserve market share, others could employ tiered pricing frameworks or value-based contracting models to mitigate margin erosion. Moreover, the tariff-induced disruptions reinforce the importance of strategic inventory management and early-warning systems that anticipate raw material shortages and transportation bottlenecks. Stakeholders that proactively adapt to these tariff shifts will be better positioned to sustain product availability and maintain competitive differentiation.

Segmenting the Market to Reveal Niche Opportunities

Assessing market segments based on drug class reveals a diversified landscape where established ACE inhibitors and ARBs coexist with emerging SGLT2 inhibitors and MRAs. While ACE inhibitors continue to serve as first-line therapy in many guidelines, the rapid uptake of SGLT2 inhibitors underscores their appeal in addressing both heart failure and comorbid conditions. Diuretics remain indispensable for symptomatic relief, yet their commodity nature drives moderate margins relative to novel biologics and hormone modulators.

When evaluating heart failure type, the dichotomy between preserved and reduced ejection fraction highlights distinct therapeutic needs and trial endpoints. Acute manifestations demand rapid intervention protocols, whereas chronic cases benefit from long-term maintenance regimens. This nuance influences both clinical trial design and commercial rollout strategies, with personalized disease management plans tailored to acute exacerbations or ongoing outpatient supervision.

The end-user dimension further delineates growth avenues: hospitals lead in administering intravenous therapies for acute flare-ups, while clinics and home care settings increasingly adopt oral formulations supported by digital adherence tools. This shift toward decentralized care models amplifies the role of patient education and remote monitoring in ensuring therapeutic compliance.

Mode-of-administration preferences continue to evolve, as patients and providers weigh the convenience of oral dosing against the rapid pharmacokinetics of intravenous injections. Meanwhile, distribution channels span e-commerce platforms that cater to digitally engaged patients, hospital pharmacies that manage inpatient needs, and retail pharmacies that facilitate community-based access. Recognizing the interplay among these layers will enable stakeholders to align market entry tactics, pricing strategies, and promotional campaigns with the unique dynamics of each segment.

Regional Variances Shaping Treatment Adoption Globally

In the Americas, robust reimbursement frameworks and strong R&D ecosystems underpin high uptake of novel heart failure therapies. Scientific collaborations between academic centers and industry have accelerated clinical trials, positioning the region at the forefront of therapeutic validation. Meanwhile, cost-containment initiatives and payer consolidations introduce pricing pressures that require nuanced value demonstrations and real-world evidence generation.

Europe, Middle East & Africa present a mosaic of market maturation levels. Western European nations combine rigorous health technology assessments with well-established care pathways, creating a predictable environment for product launches. In contrast, markets within the Middle East and Africa show heterogeneity in infrastructure and regulatory rigor, prompting manufacturers to tailor market access strategies and engage in capacity-building initiatives to ensure sustainable uptake.

Asia-Pacific epitomizes dynamic growth driven by expanding middle-class populations and evolving healthcare policies. Countries such as Japan and South Korea exhibit advanced adoption of cutting-edge therapies, while emerging markets like India and Indonesia offer vast patient pools but demand cost-sensitive pricing models. Regional partnerships and local manufacturing collaborations have become pivotal for overcoming logistical and regulatory complexities, thereby expediting market entry and scale-up.

Competitive Landscape and Leading Innovators

The competitive landscape in heart failure therapeutics is defined by leading global pharmaceutical corporations alongside agile biotech innovators. Established firms leverage their extensive commercial infrastructures to maximize reach for foundational drug classes such as ARBs and beta blockers. At the same time, emerging players with specialized pipelines are driving category expansion through first-in-class and best-in-class candidates, particularly within the SGLT2 inhibitor and peptide therapeutic spaces.

Collaborations and strategic alliances are proliferating as organizations seek to combine R&D expertise with commercialization prowess. Licensing agreements frequently center around late-stage assets, reflecting a trend toward de-risked acquisitions. In parallel, several companies are forging partnerships with digital health providers to integrate remote patient monitoring and predictive analytics into heart failure management, thereby enhancing value propositions and differentiating product offerings.

Intellectual property portfolios remain a critical battleground, with key patents underpinning blockbuster franchises and spurring patent-litigation strategies to protect market exclusivity. Observing these competitive maneuvers provides insight into future market entrants, potential generic erosion timelines, and areas where lifescience investment is most concentrated.

Strategic Imperatives for Driving Competitive Advantage

Industry leaders should prioritize investments in advanced therapeutic modalities, particularly in the SGLT2 inhibitor and MRA categories, to capitalize on the demonstrated cardiovascular benefits and growing clinician receptivity. Strengthening supply chain resilience through multi-sourcing strategies and onshore manufacturing capabilities will mitigate risks associated with tariff fluctuations and raw material scarcity.

Strategic collaborations with digital health companies can yield comprehensive solutions that integrate pharmacotherapy with remote monitoring, creating differentiated offerings that resonate with payers focused on reducing readmissions. Companies should also refine value communication frameworks by generating real-world evidence that underscores cost savings and patient outcomes improvements.

Tailored engagement with regulatory authorities to secure accelerated review pathways and conditional approvals will expeditiously position novel therapies in key markets. Finally, patient-centric educational programs and support services will enhance adherence and satisfaction, fostering brand loyalty and sustainable revenue streams.

Robust Methodological Framework Underpinning Insights

This analysis rests on a rigorous methodological framework that synthesizes primary and secondary research. We conducted in-depth interviews with a cross-section of stakeholders, including clinicians, payers, patient advocates, and industry executives, to capture qualitative insights. Complementing these perspectives, we performed a systematic review of peer-reviewed literature, clinical trial registries, regulatory filings, and company disclosures.

Quantitative data were triangulated across multiple proprietary and public sources, ensuring the validity and reliability of market dynamics, therapy adoption rates, and pipeline trajectories. Each data point underwent a multi-tier verification process, including cross-referencing with expert panels and third-party databases, to eliminate inconsistencies and reinforce analytical rigor.

Our research adhered to stringent quality assurance protocols, encompassing peer review by subject-matter experts and iterative revisions informed by stakeholder feedback. This robust approach guarantees that the findings and recommendations presented herein accurately reflect current industry realities and support evidence-based decision-making.

Synthesizing Findings to Guide Future Directions

In summary, the heart failure therapeutics domain is entering a pivotal juncture marked by scientific breakthroughs, shifting care paradigms, and evolving market forces. Stakeholders who understand the nuanced implications of drug class innovations, regulatory accelerations, and tariff-induced supply chain adjustments will secure a competitive edge. Discerning segment-specific growth drivers and regional adoption patterns is paramount to tailoring effective market entry and commercialization strategies.

As the competitive landscape intensifies, the ability to forge strategic alliances, generate compelling real-world evidence, and deliver integrated patient-centric solutions will define market leadership. By leveraging the insights and recommendations distilled in this summary, industry participants can confidently navigate uncertainties and drive sustainable innovation in heart failure therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Ace Inhibitors
    • Arbs
    • Beta Blockers
    • Diuretics
    • Mras
    • Sglt2 Inhibitors
  • Heart Failure Type
    • Preserved Ejection Fraction
      • Acute
      • Chronic
    • Reduced Ejection Fraction
      • Acute
      • Chronic
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
  • Mode Of Administration
    • Intravenous
    • Oral
  • Distribution Channel
    • E-commerce
    • Hospital Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis International AG
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Laboratoires Servier

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Heart Failure Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Ace Inhibitors
8.3. Arbs
8.4. Beta Blockers
8.5. Diuretics
8.6. Mras
8.7. Sglt2 Inhibitors
9. Heart Failure Therapeutics Market, by Heart Failure Type
9.1. Introduction
9.2. Preserved Ejection Fraction
9.2.1. Acute
9.2.2. Chronic
9.3. Reduced Ejection Fraction
9.3.1. Acute
9.3.2. Chronic
10. Heart Failure Therapeutics Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care Settings
10.4. Hospitals
11. Heart Failure Therapeutics Market, by Mode of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Heart Failure Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. E-commerce
12.3. Hospital Pharmacies
12.4. Retail Pharmacies
13. Americas Heart Failure Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Heart Failure Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Heart Failure Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis International AG
16.3.2. AstraZeneca PLC
16.3.3. Boehringer Ingelheim International GmbH
16.3.4. Pfizer Inc.
16.3.5. Eli Lilly and Company
16.3.6. Bayer AG
16.3.7. Laboratoires Servier
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEART FAILURE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. HEART FAILURE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 52. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 53. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 102. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 103. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 115. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 116. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 117. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 123. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 124. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 151. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 152. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 164. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 165. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 166. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 173. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 193. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 194. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 200. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 201. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 215. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 221. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 222. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 240. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 242. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 243. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 244. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 250. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 251. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 258. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 284. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 285. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 286. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE HE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Heart Failure Therapeutics market report include:
  • Novartis International AG
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Laboratoires Servier

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 29.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 48.18 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Heart Failure With Preserved Ejection Fraction (HFpEF) - Pipeline Insight, 2025 - Product Image

Heart Failure With Preserved Ejection Fraction (HFpEF) - Pipeline Insight, 2025

  • Drug Pipelines
  • 50 Pages
  • Global
From
EUR$1,500USDGBP
Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 331 Pages
  • Global
From
EUR$7,950USDGBP
Congestive Heart Failure (CHF) Epidemiology Forecast 2025-2034 - Product Image

Congestive Heart Failure (CHF) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
EUR$2,699USDGBP
Cardiotonic Agents - Global Strategic Business Report - Product Image

Cardiotonic Agents - Global Strategic Business Report

  • Report
  • 568 Pages
  • Global
From
EUR$5,850USDGBP
Cardiovascular Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Cardiovascular Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 118 Pages
  • Global
From
EUR$4,750USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more